Telomir Pharmaceuticals TELO Institutional Ownership

Telomir Pharmaceuticals, Inc. (NASDAQ:TELO) showed up in the 13F filings of 33 institutional investors as of June 2026.

• Their combined ownership stood at 4.9% of outstanding shares in June 2026, down from 7.1% in March 2026.
• Their total shares held in TELO increased 47.86% from the prior quarter, while the number of investors in Telomir Pharmaceuticals decreased 21.43% year over year.
• During the quarter, 17 of these 33 funds increased positions in TELO, 3 reduced exposure, and 13 held steady.
• The aggregate institutional position in Telomir Pharmaceuticals amounted to 2.98Mn shares as of June 2026, up by 963.6K shares quarter on quarter, and up 194.76K shares year over year.
• VANGUARD CAPITAL MANAGEMENT LLC holds the largest position in TELO at 1.61Mn shares as of June 30, 2026, or 2.65% of shares outstanding.
• The most significant purchases of TELO for the quarter ending June 2026 came from VANGUARD CAPITAL MANAGEMENT LLC (618.27K), GEODE CAPITAL MANAGEMENT, LLC (89.79K), VANGUARD FIDUCIARY TRUST CO (89.76K), CAPTRUST FINANCIAL ADVISORS (51.19K), Qube Research & Technologies Ltd (21.79K).
• The largest sales of TELO for the quarter ending June 2026 came from BlackRock, Inc. (8.73K), UBS Group AG (1.25K), BNP PARIBAS FINANCIAL MARKETS (5).
• Business Quant data shows the 10 biggest positions in Telomir Pharmaceuticals as of June 2026 are held by VANGUARD CAPITAL MANAGEMENT LLC (1.61Mn), GEODE CAPITAL MANAGEMENT, LLC (338.88K), BlackRock, Inc. (280.47K), VANGUARD FIDUCIARY TRUST CO (225.3K), Northern Trust Corp (61.53K), State Street Corp (58.6K), Bank of New York Mellon Corp (51.45K), CAPTRUST FINANCIAL ADVISORS (51.19K), OSAIC HOLDINGS, INC. (41.49K), World Investment Advisors (37.04K).